FDA rejects Amgen’s marketing application for osteoporosis candidate romosozumab; resubmission to include ARCH and BRIDGE data

from Stock Market News http://ift.tt/2t7o5Zg’s-marketing-application-for-osteoporosis-candidate-romosozumab;-resubmission-to-include-arch-and-bridge-data-506247

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s